President Trump could have his political fortunes buoyed by two developments that are not of his own choosing. Within hours on Wednesday night, Elon Musk announced he was departing from his ...

Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline ...

Trump’s entire negotiating philosophy was built on the premise that he could threaten economic chaos if other countries ...

Swiss President Karin Keller-Sutter will visit pharma powerhouse Ireland tomorrow for high-level talks ahead of President ...

Pharma company stocks tumbled after Donald Trump announced a plan to reduce U.S. drug prices, but regained some ground on belief the plan would be hard to implement Drug prices are expected to decline ...

HHS Secretary RFK Jr. removes the COVID-19 vaccine recommendation for healthy kids and pregnant women—the latest in a string of changes to vaccine policies; judge issues an order to halt HHS’ ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

Tariffs on pharmaceutical imports could hurt Lilly, especially with its dependence on products made in Ireland. The president ...